曼恩凱德生物醫療 MNKD 深 滬
等待開盤 12-25 09:30:00 美东时间
5.93
0.000
0.00%
華盛通- 最 高5.965
- 今 開5.965
- 成交量 90.74万股
- 最 低 5.88
- 昨 收 5.93
- 總市值 18.21亿
- 52周最高 6.68
- 市盈率 靜 61.01
- 換手率 0.30%
- 52周最低 3.3812
- 委 比 89.16%
- 總股本 3.07亿
- 歷史最高 57.40
- 量 比 0.17
- 振 幅 1.43%
- 歷史最低 0.666
- 每 手 1
- 風險率 0.81%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多MannKind Shares FUROSCIX® Business Updates
FDA approves FUROSCIX for pediatric patients weighing 43kg or above, expanding its use beyond adults with chronic heart failure and kidney disease. Additionally, five new patents for the FUROSCIX ReadyFlow Autoinjector provide extended intellectual property protection through 2040, reinforcing MannKind's position. The autoinjector, currently under FDA review, aims to deliver diuretic doses in seconds, potentially reducing hospital visits and impr...
12-23 13:05
Cartesian Therapeutics Announces the Appointment of Adrian Bot to Board of Directors
Cartesian Therapeutics appoints Adrian Bot, M.D., Ph.D., to its Board of Directors. Dr. Bot, with 30 years of experience in biopharma R&D, will join the Science and Technology Committee. His expertise in CAR T cell therapies and RNA-based medicines will support the company's pipeline and future opportunities. Bot previously led R&D at Capstan Therapeutics and contributed to CAR T development at Kite Pharma. The company’s Descartes-08 CAR-T therap...
12-18 21:05
MannKind's Furoscix Autoinjector under FDA review for expanded label
MannKind Corporation (MNKD) said that the U.S. FDA has accepted its supplemental new drug application for the Furoscix ReadyFlow Autoinjector. This device is designed to help patients administer thei...
12-01 22:21
美股大行评级 | 摩根大通上调百度至"超配"，目标价升至188美元！Navan获多家机构首予"买入"评级，目标价最高30美元
今日重点评级关注：巴克莱：维持Iovance Biotherapeutics"超配"评级，目标价从4美元升至9美元；BTIG：维持Cullinan Therapeutics"买入"评级，目标价从32美元升至38美元
11-25 10:27
Truist Securities Initiates Coverage On MannKind with Buy Rating, Announces Price Target of $9
Truist Securities analyst Gregory Renza initiates coverage on MannKind (NASDAQ:MNKD) with a Buy rating and announces Price Target of $9.
11-25 01:59
美股大行评级 | CoreWeave、Monday遭美银、小摩等多家大行下调目标价；中金首予Nebius "跑赢大市"评级，目标价143美元
今日重点评级关注：Piper Sandler：维持MeiraGTx Hldgs"超配"评级，目标价从28美元升至30美元；RBC Capital：维持4D Molecular Therapeutics"跑赢大市"评级，目标价从26美元升至32美元
11-12 11:43
Wells Fargo Maintains Overweight on MannKind, Lowers Price Target to $8
Wells Fargo analyst Benjamin Burnett maintains MannKind (NASDAQ:MNKD) with a Overweight and lowers the price target from $10 to $8.
11-11 22:33
MannKind to Present at the Jefferies Global Healthcare Conference
MannKind Corporation announced that its CEO, Michael Castagna, and CFO, Chris Prentiss, will present updates at the Jefferies London Healthcare Conference on November 19, 2025. A live audio webcast will be available on MannKind’s website, with a recording accessible for approximately 90 days post-event. MannKind is a biopharmaceutical company focusing on innovative treatments for cardiometabolic and orphan lung diseases, such as diabetes and pulm...
11-11 21:05
Mannkind rises after Q3 revenue, profit beat
MannKind Corporation (MNKD) saw a rise in its stock price after its third-quarter financial results exceeded market expectations. The company reported a quarterly revenue increase of 17.2%, reaching $...
11-05 22:56
MannKind shares are trading higher after the company reported better-than-expected Q3 financial results.
MannKind shares are trading higher after the company reported better-than-expec...
11-05 22:31
